Reduced hypertrophy in vitro after chondrogenic differentiation of adult human mesenchymal stem cells following adenoviral SOX9 gene delivery
Open Access
- 17 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Musculoskeletal Disorders
- Vol. 21 (1), 1-14
- https://doi.org/10.1186/s12891-020-3137-4
Abstract
Mesenchymal stem cell (MSC) based-treatments of cartilage injury are promising but impaired by high levels of hypertrophy after chondrogenic induction with several bone morphogenetic protein superfamily members (BMPs). As an alternative, this study investigates the chondrogenic induction of MSCs via adenoviral gene-delivery of the transcription factor SOX9 alone or in combination with other inducers, and comparatively explores the levels of hypertrophy and end stage differentiation in a pellet culture system in vitro. First generation adenoviral vectors encoding SOX9, TGFB1 or IGF1 were used alone or in combination to transduce human bone marrow-derived MSCs at 5 × 102 infectious particles/cell. Thereafter cells were placed in aggregates and maintained for three weeks in chondrogenic medium. Transgene expression was determined at the protein level (ELISA/Western blot), and aggregates were analysed histologically, immunohistochemically, biochemically and by RT-PCR for chondrogenesis and hypertrophy. SOX9 cDNA was superior to that encoding TGFB1, the typical gold standard, as an inducer of chondrogenesis in primary MSCs as evidenced by improved lacuna formation, proteoglycan and collagen type II staining, increased levels of GAG synthesis, and expression of mRNAs associated with chondrogenesis. Moreover, SOX9 modified aggregates showed a markedly lower tendency to progress towards hypertrophy, as judged by expression of the hypertrophy markers alkaline phosphatase, and collagen type X at the mRNA and protein levels. Adenoviral SOX9 gene transfer induces chondrogenic differentiation of human primary MSCs in pellet culture more effectively than TGFB1 gene transfer with lower levels of chondrocyte hypertrophy after 3 weeks of in vitro culture. Such technology might enable the formation of more stable hyaline cartilage repair tissues in vivo.This publication has 51 references indexed in Scilit:
- SOX9 gene transfer via safe, stable, replication-defective recombinant adeno-associated virus vectors as a novel, powerful tool to enhance the chondrogenic potential of human mesenchymal stem cellsStem Cell Research & Therapy, 2012
- Sox9 Directs Hypertrophic Maturation and Blocks Osteoblast Differentiation of Growth Plate ChondrocytesDevelopmental Cell, 2012
- Indian hedgehog gene transfer is a chondrogenic inducer of human mesenchymal stem cellsArthritis Research & Therapy, 2012
- Unraveling the transcriptional regulatory machinery in chondrogenesisJournal of Bone and Mineral Metabolism, 2011
- BMP12 and BMP13 gene transfer induce ligamentogenic differentiation in mesenchymal progenitor and anterior cruciate ligament cellsCytotherapy, 2010
- EnhancedIn VitroChondrogenesis of Primary Mesenchymal Stem Cells by Combined Gene TransferTissue Engineering, Part A, 2009
- Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transferArthritis Research & Therapy, 2009
- Concepts in gene therapy for cartilage repairInjury, 2008
- Major biological obstacles for persistent cell-based regeneration of articular cartilageArthritis Research & Therapy, 2007
- The state of the art of adeno-associated virus-based vectors in gene therapyVirology Journal, 2007